Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT04342936 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Classical Hodgkin Lymphoma

Interventions

DRUG: Camrelizumab
DRUG: Investigator's choice of Chemotherapy

Sponsor

Jiangsu HengRui Medicine Co., Ltd.